THERAPY DOSSIER · th-a1b6296fd242

Velafermin (rhFGF-20)

Drug

Review required. This consequential classification does not yet list attached primary citations.

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Radiation
Reported indication: Not recorded
First approval: Not recorded
Development stage: Failed in clinical trials
ChEMBL record: CHEMBL2108059 ↗
ChEMBL max phase: Not recorded
Synonyms: Velafermin; Velafermina; Velafermine; CG-53135-05
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 2

2 studies reported at therapy level; 2 evidence entries itemised.

PMID 16298938 ↗2005

Human fibroblast growth factor 20 (FGF-20; CG53135-05): a novel cytoprotectant with radioprotective potential

MouseRadiation

Extraction: mesh. Machine-extracted fields require source verification.

PMID 18464069 ↗2008

Velafermin (rhFGF-20) reduces the severity and duration of hamster cheek pouch mucositis induced by fractionated radiation

HamsterRadiation

Extraction: mesh. Machine-extracted fields require source verification.

Loading the evidence…